CoDa Therapeutics announced positive results from its Phase 2 study of Nexagon in patients with chronic venous leg ulcers. This vehicle-controlled, double-blind, three-arm study (named the NOVEL study), randomized 98 patients at multiple sites to receive low or high dose Nexagon in addition to compression bandaging. After three applications over a four-week treatment period, high-dose Nexagon demonstrated a 69% reduction in the size of venous leg ulcers. In addition, complete healing of 31% of wounds seen in the high-dose treatment arm was five times higher than complete healing in the vehicle arm.
Nexagon is a natural, unmodified antisense oligonucleotide (known as CDA001) that down-regulates the key gap junction protein Connexin43 to dampen inflammatory responses and enhance healing.